GlassScriptPhysician profile
Karen S Nipper
NPI 1124093059
$2,416.88
in general payments reported to CMS, 2019-2025
21 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $140 · 2021: $98.72 · 2022: $223 · 2023: $385 · 2024: $566 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613 · Long Term Medical Supply Or Device Loan: $29.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.56 |
| Long Term Medical Supply Or Device Loan | $29.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $552.23 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $518.84 | 2024-2025 | Xdemvy |
| Abbvie INC. | $240.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $195.29 | 2019-2023 | |
| Allergan, INC. | $144.55 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $141.80 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Amgen INC. | $113.97 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $112.30 | 2022-2023 | Cirrus Hd-Oct |
| Dompe US, INC. | $69.41 | 2025 | Oxervate |
| Alcon Vision LLC | $59.39 | 2020-2023 | Eysuvis |
| Oyster Point Pharma, INC. | $33.00 | 2023-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.96 | 2020-2021 | |
| Rxsight INC | $27.12 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Ani Pharmaceuticals, INC. | $26.11 | 2024 | Purified Cortrophin Gel |
| Springworks Therapeutics, INC. | $25.73 | 2025 | Gomekli |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $23.82 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $23.28 | 2025 | Tecnis Iol |
| Horizon Therapeutics Plc | $22.43 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $18.97 | 2022 | |
| Tearlab Corp | $16.23 | 2024 | Scoutpro Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Nipper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.